[EN] METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS<br/>[FR] MÉTABOLITES DE 2-(FURAN-2-YL)-7-(2-(4-(4-(2-MÉTHOXYÉTHOXY)PHÉNYL)PIPÉRAZIN-1-YL)ÉTHYL)-7H-PYRAZOLO[4,3-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-AMINE ET LEUR UTILITÉ EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE
申请人:MERCK SHARP & DOHME
公开号:WO2012135084A1
公开(公告)日:2012-10-04
The present invention provides a compound of the (formula:(I) or a pharmaceutically acceptable salt thereof in isolated and purified form. The compound is an adenosine A2a receptor antagonists useful in treatment of central nervous system disorders, such as Parkinsons disease, Extra-Pyramidal Syndrome (EPS) caused by treatment with an antipsychotic agent, restless legs syndrome, Huntington s disease, attention disorders, depression, stroke and psychoses.
本发明提供了一种化合物(化学式:(I)或其在分离和纯化形式中的药用可接受盐。该化合物是一种腺苷A2a受体拮抗剂,用于治疗中枢神经系统疾病,如帕金森病、由抗精神药物引起的额外锥体综合征(EPS)、不宁腿综合征、亨廷顿病、注意障碍、抑郁症、中风和精神病。